International Assets Investment Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-28,000
Closed -$7.28K – 2441
2026
Q1
$7.28K Hold
28,000
– – ﹤0.01% 1766
2025
Q4
$11.8K Buy
+28,000
New +$14.8K ﹤0.01% 1615
2025
Q3
– Sell
-34,000
Closed -$18.4K – 862
2025
Q2
$18.4K Buy
+34,000
New +$20.2K ﹤0.01% 841
2025
Q1
– Sell
-36,550
Closed -$41.3K – 867
2024
Q4
$41.3K Sell
36,550
-3,550
-9% -$6.49K ﹤0.01% 809
2024
Q3
$34.7K Sell
40,100
-1,035
-3% -$758 ﹤0.01% 1193
2024
Q2
$14.7K Buy
41,135
+6,500
+19% +$3.51K ﹤0.01% 1555
2024
Q1
$21K Buy
+34,635
New +$25.1K ﹤0.01% 767
2023
Q2
– Sell
-1,100
Closed -$1.94K – 888
2023
Q1
$1.94K Buy
+1,100
New +$3.14K ﹤0.01% 997
2021
Q2
– Sell
-750
Closed -$9K – 1649
2021
Q1
$9K Buy
+750
New +$10.1K ﹤0.01% 1607

Other funds holding SGMO

International Assets Investment Management's SGMO Position: Q2 2026 in Review

International Assets Investment Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2026, closing a stake of 28,000 shares — an estimated $7.28K sold.

International Assets Investment Management first reported a position in SGMO in Q1 2021 and held it in 9 quarters. The position peaked at $41.3K in Q4 2024. 6 funds tracked by Wall St. Rank hold SGMO as of Q2 2026.

  • International Assets Investment Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2026 after selling out during the quarter.
  • International Assets Investment Management sold 28,000 SANGAMO THERAPEUTICS INC shares in Q2 2026, an estimated $7.28K.
  • International Assets Investment Management first reported a position in SANGAMO THERAPEUTICS INC in Q1 2021 and held it in 9 quarters.
  • International Assets Investment Management's SANGAMO THERAPEUTICS INC position peaked at $41.3K in Q4 2024.
  • 6 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2026.

Based on International Assets Investment Management's 13F filing for Q2 2026, filed 22 Jul 2026.